Xu Yiming, Li Qiuping, Mao Siyi, Yang Kun, Yang Shuya
Regiment Four of Cadets, Basic Medical Science Academy, Air Force Medical University, Xi'an 710032, China.
Department of Immunology, Basic Medical Science Academy, Air Force Medical University, Xi'an 710032, China. *Corresponding authors, E-mail:
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2024 Dec;40(12):1115-1120.
Alzheimer's disease (AD) is a neurodegenerative disorder with an insidious onset, primarily characterized by a progressive decline in cognitive function. MCP-1 is a cytokine with chemotactic effects on monocytes, which can regulate their migration and infiltration and participate in disease progression. Increasing evidence suggests that MCP-1 plays a key role in the progression of Alzheimer's disease and has the potential to act as an early diagnostic marker and intervention target. This paper reviews the regulatory role of MCP-1 in neuroinflammation, beta-amyloid (Aβ) deposition and Tau pathology, and explores the potential of MCP-1 as a biomarker and intervention target for the early diagnosis of Alzheimer's disease.
阿尔茨海默病（AD）是一种起病隐匿的神经退行性疾病，主要特征是认知功能进行性下降。单核细胞趋化蛋白-1（MCP-1）是一种对单核细胞具有趋化作用的细胞因子，可调节其迁移和浸润，并参与疾病进展。越来越多的证据表明，MCP-1在阿尔茨海默病的进展中起关键作用，并有潜力作为早期诊断标志物和干预靶点。本文综述了MCP-1在神经炎症、β-淀粉样蛋白（Aβ）沉积和Tau病理中的调节作用，并探讨了MCP-1作为阿尔茨海默病早期诊断的生物标志物和干预靶点的潜力。
